444 related articles for article (PubMed ID: 32884060)
1. Efficacy and safety of posaconazole for the prevention of invasive fungal infections in immunocompromised patients: a systematic review with meta-analysis and trial sequential analysis.
Wong TY; Loo YS; Veettil SK; Wong PS; Divya G; Ching SM; Menon RK
Sci Rep; 2020 Sep; 10(1):14575. PubMed ID: 32884060
[TBL] [Abstract][Full Text] [Related]
2. Posaconazole: an extended-spectrum triazole antifungal agent.
Schiller DS; Fung HB
Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
[TBL] [Abstract][Full Text] [Related]
3. Network Meta-analysis and Pharmacoeconomic Evaluation of Fluconazole, Itraconazole, Posaconazole, and Voriconazole in Invasive Fungal Infection Prophylaxis.
Zhao YJ; Khoo AL; Tan G; Teng M; Tee C; Tan BH; Ong B; Lim BP; Chai LY
Antimicrob Agents Chemother; 2016 Jan; 60(1):376-86. PubMed ID: 26525782
[TBL] [Abstract][Full Text] [Related]
4. Mixed treatment comparison of prophylaxis against invasive fungal infections in neutropenic patients receiving therapy for haematological malignancies: a systematic review.
Pechlivanoglou P; Le HH; Daenen S; Snowden JA; Postma MJ
J Antimicrob Chemother; 2014 Jan; 69(1):1-11. PubMed ID: 23975736
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Antifungal Prophylaxis Drugs in Patients With Hematological Disease or Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review and Network Meta-analysis.
Wang J; Zhou M; Xu JY; Zhou RF; Chen B; Wan Y
JAMA Netw Open; 2020 Oct; 3(10):e2017652. PubMed ID: 33030550
[TBL] [Abstract][Full Text] [Related]
6. Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients.
Cortegiani A; Russotto V; Maggiore A; Attanasio M; Naro AR; Raineri SM; Giarratano A
Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD004920. PubMed ID: 26772902
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of voriconazole in immunocompromised patients: systematic review and meta-analysis.
Rosanova MT; Bes D; Serrano Aguilar P; Sberna N; Lede R
Infect Dis (Lond); 2018 Jul; 50(7):489-494. PubMed ID: 29262742
[TBL] [Abstract][Full Text] [Related]
8. Antifungal agents for preventing fungal infections in solid organ transplant recipients.
Playford EG; Webster AC; Sorell TC; Craig JC
Cochrane Database Syst Rev; 2004; (3):CD004291. PubMed ID: 15266524
[TBL] [Abstract][Full Text] [Related]
9. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis.
Ziakas PD; Kourbeti IS; Mylonakis E
Clin Ther; 2014 Feb; 36(2):292-306.e1. PubMed ID: 24439393
[TBL] [Abstract][Full Text] [Related]
10. Primary Fungal Prophylaxis in Hematological Malignancy: a Network Meta-Analysis of Randomized Controlled Trials.
Lee CH; Lin C; Ho CL; Lin JC
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866872
[TBL] [Abstract][Full Text] [Related]
11. Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients.
Bow EJ; Vanness DJ; Slavin M; Cordonnier C; Cornely OA; Marks DI; Pagliuca A; Solano C; Cragin L; Shaul AJ; Sorensen S; Chambers R; Kantecki M; Weinstein D; Schlamm H
BMC Infect Dis; 2015 Mar; 15():128. PubMed ID: 25887385
[TBL] [Abstract][Full Text] [Related]
12. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials.
Playford EG; Webster AC; Sorrell TC; Craig JC
J Antimicrob Chemother; 2006 Apr; 57(4):628-38. PubMed ID: 16459344
[TBL] [Abstract][Full Text] [Related]
13. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.
Ullmann AJ; Lipton JH; Vesole DH; Chandrasekar P; Langston A; Tarantolo SR; Greinix H; Morais de Azevedo W; Reddy V; Boparai N; Pedicone L; Patino H; Durrant S
N Engl J Med; 2007 Jan; 356(4):335-47. PubMed ID: 17251530
[TBL] [Abstract][Full Text] [Related]
14. The cost-utility analysis of antifungal prophylaxis for invasive fungal infections in acute myeloid leukaemia patients receiving chemotherapy: a study from a middle-income country.
Pungprasert T; Dhirachaikulpanich D; Phutthasakda W; Tantai N; Maneeon S; Nganthavee V; Atipas K; Tanpong S; Krithin S; Tanglitanon S; Jutidamrongphan W; Chayakulkeeree M; Srinonprasert V; Phikulsod P
J Hosp Infect; 2024 Mar; 145():118-128. PubMed ID: 38219835
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients.
Park S; Kim K; Jang JH; Kim SJ; Kim WS; Chung DR; Kang CI; Peck KR; Jung CW
J Infect; 2016 Nov; 73(5):496-505. PubMed ID: 27394404
[TBL] [Abstract][Full Text] [Related]
16. Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.
Cho SY; Lee DG; Choi JK; Lee HJ; Kim SH; Park SH; Choi SM; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS; Back H; Kang S; Lee EK
Clin Ther; 2015 Sep; 37(9):2019-27. PubMed ID: 26188835
[TBL] [Abstract][Full Text] [Related]
17. Patients at high risk of invasive fungal infections: when and how to treat.
Rüping MJ; Vehreschild JJ; Cornely OA
Drugs; 2008; 68(14):1941-62. PubMed ID: 18778118
[TBL] [Abstract][Full Text] [Related]
18. Network meta-analysis of triazole, polyene, and echinocandin antifungal agents in invasive fungal infection prophylaxis in patients with hematological malignancies.
Zeng H; Wu Z; Yu B; Wang B; Wu C; Wu J; Lai J; Gao X; Chen J
BMC Cancer; 2021 Apr; 21(1):404. PubMed ID: 33853560
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of micafungin versus extensive azoles in the prevention and treatment of invasive fungal infections for neutropenia patients with hematological malignancies: A meta-analysis of randomized controlled trials.
Lee CH; Lin JC; Ho CL; Sun M; Yen WT; Lin C
PLoS One; 2017; 12(7):e0180050. PubMed ID: 28700646
[TBL] [Abstract][Full Text] [Related]
20. Posaconazole vs fluconazole/itraconazole in the prophylaxis of invasive fungal infections in immunocompromised patients: a cost-effectiveness analysis in Greece.
Athanasakis K; Petrakis I; Kyriopoulos J
J Med Econ; 2013; 16(5):678-84. PubMed ID: 23448409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
